Business Context and Reporting Period
This Form 6-K filing by Grifols, S.A. is dated July 30, 2024, and discloses relevant information regarding the restatement of comparative figures in the Condensed Consolidated Interim Financial Statements for the first half of 2024. The restatement was necessitated by incorrect accounting treatments identified during a limited review conducted by Deloitte Auditores, S.L., and discussions with the Spanish securities regulator (CNMV).
Key Financial Metrics and Adjustments
The filing details specific financial adjustments resulting from two primary accounting corrections:
- ITK JV Restatement: Due to reclassifying the Biotek America LLC joint venture from a financial investment to a joint operation, comparative figures for the first half of 2023 were restated. This resulted in a reduction of net income by €14 million and EBITDA by €12 million for that period.
- SRAAS Equity Correction: An error in the accounting treatment of non-controlling interests in Shanghai RAAS Blood Products Co. Limited (SRAAS) led to an overstatement of "Investment in equity-accounted investees" by €113 million, "Non-current assets held for sale" by €344 million, and "Consolidated reserves" by €457 million as of December 31, 2023.
- Income Statement Impact: The SRAAS correction had no impact on the income statement or results for financial years 2020 to 2023, as it was a balance sheet reclassification. However, it ensures the net gain from the 2024 sale of the 20% SRAAS stake is accurately accounted for.
Material Changes Versus Prior Periods
Material changes involve the retroactive adjustment of historical financial data to correct prior errors:
- First Half 2023: Net income and EBITDA were reduced by €14 million and €12 million, respectively, to reflect the correct accounting for the ITK JV.
- Full Year 2023: Future restatements in the 2024 annual accounts will reflect a reduction in net income of €17 million and EBITDA of €13 million.
- Full Year 2022: Future restatements will reflect a reduction in net income of €23 million and EBITDA of €20 million.
- Balance Sheet: Consolidated reserves as of December 31, 2023, were reduced by €38 million due to the ITK JV adjustment and €457 million due to the SRAAS correction.
Guidance, Outlook, and Risks
The filing does not provide updated forward-looking guidance or management commentary on future operational performance. However, it addresses significant regulatory and accounting risks:
- Regulatory Compliance: Grifols confirms it has responded to all information requests from the CNMV regarding the accounting treatment of the Immunotek agreement.
- Auditor Review: Deloitte Auditores, S.L. conducted a limited review of the interim financial statements as of June 30, 2024, including the restatements. The auditor found no matters indicating the statements were not prepared in accordance with IAS 34.
- Unusual Items: The restatements are classified as corrections of errors under IAS 8 rather than operational changes, though they significantly alter historical profitability metrics.
Investor Verification Checklist
- Verify the updated Condensed Consolidated Interim Financial Statements for the first half of 2024 to confirm the restated net income and EBITDA figures.
- Review the upcoming 2024 Annual Report to confirm the restatement of full-year 2022 and 2023 figures as disclosed in this filing.
- Assess the impact of the €457 million reduction in consolidated reserves on the company's equity position and leverage ratios.
- Confirm the accuracy of the net gain recorded from the 2024 sale of the 20% stake in SRAAS following the carrying value adjustment.
- Monitor any further communications from the CNMV regarding the accounting treatment of the ITK JV and SRAAS transactions.